Mario E. Lacouture on the Psychosocial Impact of Dermatologic AEs

Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Oncology nurses provide patients with lung cancer the education and empathy needed to navigate treatment options and adverse event management.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

The first real-time, non-invasive skin cancer evaluation system has received clearance from the FDA.

Lifileucel is the first TIL therapy approved by the FDA for a solid tumor, specifically previously treated unresectable or metastatic melanoma.